MarginsXMarginsX
Home › Markets › Health Care › AVLN

Avalyn Pharma Inc. (AVLN)

AVLN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$29.76
-1.72% on the day
Market cap
$1.3B
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerAVLN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0001540171
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
17.5 months
$145.4M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$20.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Going Concern The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued."
10-Q 2026-11-12
Cash and burn$145.4M cash; operating cash flow -$24.9M a quarter.Report 2026-09-30
Shares outstanding44,521,494 (2026-11-10).Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $20.0M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$29.7M-$26.3M$145.4M$14.8MNeeds four quarters10-Q 2026-11-12
Q3 2026
2026-06-30
Not filed-$28.9M-$26.1M$264.2M$14.8MNeeds four quarters10-Q 2026-11-12
Q3 2026
2026-03-31
Not filed-$26.9M-$29.9M$92.3M$14.8MNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-09-30
Not filed-$23.6M-$17.3M$27.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-06-30
Not filed-$20.2M-$20.7M$61.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-03-31
Not filed-$17.5M-$19.3M$28.8MNo debt tagsNeeds four quarters10-Q 2026-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-04-30
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 66 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.9%
1 month+27.5%
3 months-17.2%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-22.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OCULOcular Therapeutix Inc.$6.01-3.22%$1.3B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B
INVAInnoviva Inc.$18.49-2.84%$1.3B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
MLYSMineralys Therapeutics Inc.$14.53-5.22%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier